Business Wire

Prevailion Named a 2020 Gartner “Cool Vendor” in Security Operations and Threat Intelligence Field

Share

Prevailion, a global leader in cyber adversary intelligence, today announced that it has been recognized as a Gartner Cool Vendor in the latest Cool Vendors in Security Operations and Threat Intelligence report.

The Gartner report profiles “emerging vendors that security and risk management leaders should consider when evaluating emerging threats requiring the latest in security operations technologies.” Gartner writes that: “Security and risk management leaders are seeking solutions for better visibility into their IT environments to help strengthen their security posture, as well as prioritize security control gaps and remediation activities based on business risk.” It also notes that: “Organizations struggle to mitigate vulnerabilities because of the inability to prioritize them due to a lack of context about the assets and external threat environment.”*

This lack of visibility into active and emerging threats poses a major challenge to organizational cybersecurity, and is the primary focus of Prevailion. Through a global constellation of clandestine sensors, Prevailion actively monitors thousands of cyber attacks in real-time, including billions of malware communications, providing an unprecedented level of adversary intelligence that companies can use to protect their networks.

“We are honored to be selected by Gartner, which we believe validates the core technology behind our platform and the hard work and dedication of our team,” said Karim Hijazi, founder and CEO of Prevailion. “At Prevailion, we have been charting a new course in the field of threat intelligence, by empowering companies with greater visibility into the threat actors targeting their networks and the networks of their closest partners. By going after the attackers’ own infrastructure, we can provide companies with unprecedented insights into criminal and nation-state hackers’ malicious activity and list of targets. This enables corporate security teams to better prioritize threats, by focusing immediately on confirmed attacks, rather than having to rely on noisy and error-prone security alerts or vague risk scorecards.”

EXCLUSIVE INSIGHTS INTO CYBER THREAT ACTIVITY

Prevailion is currently tracking over 28,000 compromised organizations around the world, ranging from publicly traded companies and their supply chain partners to governments, universities, NGOs and more. Many of the cyber compromises Prevailion has observed are undetected or unreported by the victim organizations.

According to Prevailion’s exclusive intelligence, 22% of the Fortune 500 are showing active or recent compromise activity by criminal or state-affiliated hackers. This includes 79% of software companies and 64% of pharmaceuticals, which are the most heavily targeted industries, based on recent cyber activity.

Prevailion’s unique cyber intelligence capability allows it to detect active compromises inside corporate networks that do not require any access or confirmation by the affected corporation. To do this, Prevailion’s intelligence team targets criminal networks in order to intercept communications between the hackers’ “command-and-control” servers and the malware they’ve deployed. This ability to eavesdrop on criminal activity gives Prevailion significantly enhanced insights into real-time hacking operations taking place all over the world. It also allows them to anticipate new attacks ahead of time.

Prevailion’s APEX Platform is a reliable source of information on thousands of unreported corporate breaches, and provides around-the-clock intelligence on new compromises, escalating breach activity and corporate remediation efforts.

*Gartner “Cool Vendors in Security Operations and Threat Intelligence,” Mitchell Schneider, Ruggero Contu, John Watts, Craig Lawson, October 13, 2020.

GARTNER DISCLAIMER

Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.

ABOUT PREVAILION

Prevailion is a compromise intelligence company, transforming the way organizations approach risk mitigation and business decision-making. Through next-level tailored intelligence and a zero-touch platform, Prevailion provides a full view of confirmed “Evidence of Compromise” (EOC) for customers and their partner ecosystems. To learn more about Prevailion, visit www.prevailion.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michael Sias
inquiry@firm19.com
954-361-3963

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

A-CAP Announces Successful Divestiture of Standard de Liège SA and Immobilière du Standard de Liège SRL6.6.2025 23:32:00 EEST | Press release

Advantage Capital Holdings, LLC (“A-CAP” or “The Company”), a New York-based insurance and financial services company with over $12 billion in assets, today announced the successful divestiture of Standard de Liège SA (“Standard Liège” or the “Club”), one of Belgium's most historic soccer clubs, and Immobilière du Standard de Liège SRL, the corporate entity that owns the Club's stadium, Maurice Dufrasne Stadium, to a consortium of buyers led by Standard Liège Chief Executive Officer Giacomo Angelini. This transaction marks the end of 777 Partners’ legacy involvement with the Club and sets the stage for the Club’s future growth and success, both on and off the field. Benefits of the transaction include: Increased stability across the Club’s shareholder base, which clears the path for future investments, Operational clarity, establishing a unified direction that will allow both players and management to fully concentrate on on-field performance, ensuring that collective focus remains on

Populous Acquires Fentress Architects, Expanding Global Aviation Portfolio6.6.2025 21:00:00 EEST | Press release

Populous, the world-renowned design firm specializing in sport and entertainment venues, today announced the acquisition of Denver-based Fentress Architects, a global leader in iconic aviation projects and prominent public buildings, including convention centers, museums and government facilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606849000/en/ Los Angeles International Airport. Designed by Fentress Architects. This strategic acquisition unites two of the most respected names in architecture, combining Populous’ unparalleled expertise in designing memorable experiences with Fentress’ award-winning portfolio of aviation, civic and cultural landmarks. The acquisition significantly broadens the scope and scale of services that Populous can offer clients across the globe. Bruce Miller, Populous Global Chair and CEO, commented: “We are committed to expanding the breadth of our practice. Fentress Architects has lon

Vertex Presents New Data on Benefits of ALYFTREK ® and Importance of Achieving Lower Sweat Chloride Levels at the European Cystic Fibrosis Conference6.6.2025 19:00:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data across multiple studies demonstrating positive clinical and quality of life benefits of treatment with CFTR modulators and, in particular, ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor), which is approved in the United States and United Kingdom and is currently under review with health authorities in the EU, Canada, Australia, New Zealand and Switzerland. These data were presented at this year’s European Cystic Fibrosis Society’s (ECFS) 48th European Cystic Fibrosis Conference held June 4-7, 2025, in Milan, Italy. During the conference, the Company presented data from a pooled analysis across CFTR modulators, including ALYFTREK, which demonstrate that reduction in sweat chloride (SwCl), and therefore greater restoration of CFTR function, is associated with improved outcomes in people with cystic fibrosis (CF). For all clinical outcomes in the study, SwCl levels below 60 mmol/L were associated with greater benefit

IBSA Derma at IMCAS Asia 2025: spotlight on the future of aesthetic medicine in the 10 th Anniversary Year of NAHYCO ® Technology6.6.2025 17:00:00 EEST | Press release

IBSA Derma – the dermoaesthetic division of IBSA – once again confirms its leadership in the international aesthetic medicine landscape by participating in the 18th edition of IMCAS Asia, taking place from June 6 to 8 in Bangkok, Thailand. With over 3,000 attendees expected, the event represents a key opportunity for physicians and experts to share the latest innovations and cutting-edge advancements in aesthetic procedures and treatments, staying at the forefront of this dynamic field. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603094257/en/ IBSA’s stand at IMCAS Asia 2025 As part of the congress, IBSA Derma will host a scientific symposium titled “The Future of Tissue Regeneration with NAHYCO® Technology. Feeling and Seeing the Results with Profhilo® Line” scheduled for Saturday, June 7, from 3:00 to 4:00 pm ICT in Room 1 - Level 2. Internationally renowned speakers – Dr. Lam Bee Lan and Prof. Ofir Artzi – will lead

HistoSonics Completes Enrollment in #HOPE4KIDNEY Trial Evaluating Non-Invasive Histotripsy to Treat Kidney Tumors6.6.2025 15:00:00 EEST | Press release

HistoSonics, Inc., the manufacturer of the Edison® Histotripsy System and novel histotripsy therapy platforms, today announced the completion of patient enrollment in its pivotal #HOPE4KIDNEY trial. This prospective, multi-center, single-arm trial is designed to evaluate the safety and effectiveness of the Edison System in destroying kidney tissue by treating primary solid kidney tumors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250606659747/en/ Edison Histotripsy System Procedure for Kidney Tumor Animation The trial enrolled patients with a single, non-metastatic solid kidney mass ≤3 cm, confirmed by imaging and biopsy. Subjects will be followed for five years post-procedure, with evaluations at multiple time points, including 14-day, 30-day, 90-day, 180-day, and annual assessments. The Edison System remains in investigational use for kidney applications and is not yet FDA-approved for this indication. Data from the #H

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye